Nirmatrelvir/Ritonavir
INDICATIONS
FDA
FDA
The FDA fully approved (2023) drug after initial Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and children ≥ 12 years of age who are at high risk for progressing to severe COVID-19 illness, including hospitalization and death.
- Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients >60 years of age.
- The FDA removed an earlier requirement for a positive SARS-CoV-2 test from the EUA in February 2023.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 12, 2023
Citation
Auwaerter, Paul G, and Kathryn Dzintars. "Nirmatrelvir/Ritonavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540766/all/Nirmatrelvir_Ritonavir.
Auwaerter PG, Dzintars K. Nirmatrelvir/Ritonavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540766/all/Nirmatrelvir_Ritonavir. Accessed October 9, 2024.
Auwaerter, P. G., & Dzintars, K. (2023). Nirmatrelvir/Ritonavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540766/all/Nirmatrelvir_Ritonavir
Auwaerter PG, Dzintars K. Nirmatrelvir/Ritonavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 October 09]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540766/all/Nirmatrelvir_Ritonavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nirmatrelvir/Ritonavir
ID - 540766
A1 - Auwaerter,Paul,M.D.
AU - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/11/12/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540766/all/Nirmatrelvir_Ritonavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -